Tech Company Financing Transactions
Hemoshear Funding Round
On 2/17/2021, Hemoshear raised $40 million in Series A investment from Suvretta Capital Management, Adage Capital Management and Janus Henderson Investors.
Transaction Overview
Company Name
Announced On
2/17/2021
Transaction Type
Venture Equity
Amount
$40,000,000
Round
Series A
Investors
Suvretta Capital Management (Lead Investor) (David Friedman)
Proceeds Purpose
The company intends to use the funds to complete a phase 2 study of its lead compound, HST5040, an investigational oral small molecule therapy, for the treatment of methylmalonic acidemia (MMA) and propionic acidemia (PA), as well as fund future clinical studies and earlier stage programs.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
501 Locust Ave. 301
Charlottesville, VA 22902
USA
Charlottesville, VA 22902
USA
Phone
Website
Email Address
Overview
Unlocking human disease biology at a level not possible until now. THINK HUMAN.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jim Powers
Chief Financial Officer
Aric Holsinger
Chief Medical Officer
Gerry Cox
Chief Operating Officer
Brian Wamhoff
Chief Scientific Officer
Brian Johns
VP - Bus. Development
Michael Innes
VP - Marketing
Susan Klees
VP - Operations
Michael Simmers
VP - Operations
Mavis Waller
VP - Regulatory Affairs
Mark Hayes
Browse more venture capital transactions:
Prev: 2/17/2021: Iterion Therapeutics venture capital transaction
Next: 2/17/2021: Strata Identity venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. All VC database entries reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs